Paper745013
Absence of "cheese effect" during deprenyl therapy: some recent studies.
Sandler M and 3 others. J Neural Transm, 1978. Cited by 36 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Absence of "cheese effect" during deprenyl therapy: some recent studies. Papers, record 745013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/745013
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Phenethylamines | Major topic |
| Selegiline | Major topic |
| Amphetamines | |
| Animals | |
| Blood Pressure | |
| Humans | |
| Intestines | |
| Monoamine Oxidase | |
| Parkinson Disease | |
| Substrate Specificity | |
| Swine | |
| Tyramine |
Source PubMed
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25,150 | The effect of urinary pH and flow rate on monoamine output. | Clin Chim Acta | 1978 | https://conductscience.org/library/papers/25150 | PubMed |
| 2 | 4,943,186 | Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. | Psychopharmacologia | 1970 | https://conductscience.org/library/papers/4943186 | PubMed |
| 3 | 637,437 | Isoniazid and reaction to cheese. | Ann Intern Med | 1978 | https://conductscience.org/library/papers/637437 | PubMed |
| 4 | 71,602 | Deprenyl in Parkinson's disease. | Lancet | 1977 | https://conductscience.org/library/papers/71602 | PubMed |
| 5 | 834,248 | Dopamine is a monoamine oxidase B substrate in man. | Nature | 1977 | https://conductscience.org/library/papers/834248 | PubMed |
| 6 | 65,560 | Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. | Lancet | 1977 | https://conductscience.org/library/papers/65560 | PubMed |
| 7 | 5,054,207 | Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. | Adv Biochem Psychopharmacol | 1972 | https://conductscience.org/library/papers/5054207 | PubMed |
| 8 | 6,056,555 | Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250"). | Acta Med Acad Sci Hung | 1967 | https://conductscience.org/library/papers/6056555 | PubMed |
| 9 | 656,120 | Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment. | Biochem Pharmacol | 1978 | https://conductscience.org/library/papers/656120 | PubMed |
| 10 | 4,748,552 | Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain. | J Pharmacol Exp Ther | 1973 | https://conductscience.org/library/papers/4748552 | PubMed |
| 11 | 96,466 | Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. | Psychopharmacology (Berl) | 1978 | https://conductscience.org/library/papers/96466 | PubMed |
| 12 | 745,017 | Recent observations on the clinical pharmacology of (-)deprenyl. | J Neural Transm | 1978 | https://conductscience.org/library/papers/745017 | PubMed |
| 13 | 745,014 | On the mode of action of L-deprenyl in the human central nervous system. | J Neural Transm | 1978 | https://conductscience.org/library/papers/745014 | PubMed |
| 14 | 5,659,776 | Some observations upon a new inhibitor of monoamine oxidase in brain tissue. | Biochem Pharmacol | 1968 | https://conductscience.org/library/papers/5659776 | PubMed |
| 15 | 4,384,242 | Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. | Biochem Pharmacol | 1968 | https://conductscience.org/library/papers/4384242 | PubMed |
| 16 | 728,327 | Deprenyl is metabolized to methamphetamine and amphetamine in man. | Br J Clin Pharmacol | 1978 | https://conductscience.org/library/papers/728327 | PubMed |
| 17 | 745,011 | The possible mechanisms of action of (-)deprenyl in Parkinson's disease. | J Neural Transm | 1978 | https://conductscience.org/library/papers/745011 | PubMed |
| 18 | 934,359 | Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. | Naunyn Schmiedebergs Arch Pharmacol | 1976 | https://conductscience.org/library/papers/934359 | PubMed |
| 19 | 1,172,524 | The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. | J Neural Transm | 1975 | https://conductscience.org/library/papers/1172524 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 28,282,815 | The MPTP Story. | J Parkinsons Dis | 2017 | https://conductscience.org/library/papers/28282815 | PubMed |
| 27,480,491 | The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). | Mol Psychiatry | 2016 | https://conductscience.org/library/papers/27480491 | PubMed |
| 22,872,464 | Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029). | Neurotox Res | 2013 | https://conductscience.org/library/papers/22872464 | PubMed |
| 22,802,692 | Adjunctive therapy in Parkinson's disease: the role of rasagiline. | Neuropsychiatr Dis Treat | 2012 | https://conductscience.org/library/papers/22802692 | PubMed |
| 21,850,574 | Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. | Naunyn Schmiedebergs Arch Pharmacol | 2011 | https://conductscience.org/library/papers/21850574 | PubMed |
| 15,537,168 | In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog. | Eur J Drug Metab Pharmacokinet | 2004 | https://conductscience.org/library/papers/15537168 | PubMed |
| 11,607,046 | Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. | CNS Drug Rev | 2001 | https://conductscience.org/library/papers/11607046 | PubMed |
| 6,791,202 | Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. | Psychopharmacology (Berl) | 1981 | https://conductscience.org/library/papers/6791202 | PubMed |
| 6,777,463 | Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. | J Neurol Neurosurg Psychiatry | 1980 | https://conductscience.org/library/papers/6777463 | PubMed |
| 6,437,857 | The pharmacology of Parkinson's disease: basic aspects and recent advances. | Experientia | 1984 | https://conductscience.org/library/papers/6437857 | PubMed |
| 3,929,314 | Tyramine pressor sensitivity changes during deprenyl treatment. | Psychopharmacology (Berl) | 1985 | https://conductscience.org/library/papers/3929314 | PubMed |
| 3,928,010 | Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. | Br J Pharmacol | 1985 | https://conductscience.org/library/papers/3928010 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/745013
GET https://conductscience.org/api/papers/v1/745013/authors